ZyVersa Therapeutics Accounts Payable

The latest accounts payable for ZVSA is $10M as of March 2026. That compares with $9.6B in the prior-year period — down 99.9% year over year. Investors often review this figure alongside ZyVersa Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, ZVSA's accounts payable moved from $9.6B to $10M — a 99.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in ZyVersa Therapeutics's operating scale or balance-sheet position.

A accounts payable figure of $10M for ZVSA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting ZVSA's accounts payable ($10M), review year-over-year change from $9.6B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.